📊 ANVS Key Takeaways
Is Annovis Bio, Inc. (ANVS) a Good Investment?
Annovis Bio is a pre-revenue pharmaceutical company with severe financial distress: zero product revenue, negative free cash flow of -$9M annually, and a current ratio of 0.61x indicating acute liquidity stress. With only ~$14.2M in cash and burning $9M per year, the company faces potential insolvency within 18 months absent significant capital raises or clinical success.
Annovis Bio remains a pre-revenue biotechnology company with no commercial income, persistent operating losses, and materially negative operating cash flow. Its balance sheet is currently supported by a large cash position and no long-term debt, but the business model still depends on converting R&D spending into clinical and regulatory progress before liquidity weakens further.
Annovis Bio, Inc. Key Strengths (ANVS)
- No long-term debt eliminates near-term solvency risk from external creditors
- Maintains positive cash reserves of $14.2M providing limited runway for operations and clinical development
- Biotech/pharma sector expectation of losses during pre-commercial development phase is standard
- Strong cash balance relative to liabilities supports near-term operations
- Debt-free capital structure reduces financial distress risk
- Improved diluted EPS suggests some loss containment on a per-share basis
ANVS Stock Risks: Annovis Bio, Inc. Investment Risks
- Zero revenue generation with no evidence of commercially viable products
- Negative operating cash flow of -$9M annually with limited cash runway (~1.5 years at current burn rate)
- Current ratio of 0.61x signals short-term liquidity crisis and potential inability to meet obligations
- Massive operating losses of -$18M indicate unsustainable business model without product approval
- Severely negative returns (ROE -563%, ROA -108%) demonstrate substantial shareholder value destruction
- No revenue base means fundamentals depend entirely on future pipeline execution
- High cash burn and negative operating cash flow could force future capital raises
- Very weak returns on equity and assets show poor current capital efficiency
Key Metrics to Watch
- Quarterly cash burn rate and months of cash remaining
- Clinical trial progression milestones and FDA regulatory updates
- Capital raise announcements and dilutive financing events
- Licensing or partnership agreements that could generate revenue
- Quarterly operating cash burn versus cash balance
- Clinical, regulatory, and partnership milestones that could convert the company from pre-revenue to funded growth
Annovis Bio, Inc. (ANVS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ANVS Profit Margin, ROE & Profitability Analysis
ANVS vs Healthcare Sector: How Annovis Bio, Inc. Compares
How Annovis Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Annovis Bio, Inc. Stock Overvalued? ANVS Valuation Analysis 2026
Based on fundamental analysis, Annovis Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Annovis Bio, Inc. Balance Sheet: ANVS Debt, Cash & Liquidity
ANVS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Annovis Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.31 indicates the company is currently unprofitable.
ANVS Revenue Growth, EPS Growth & YoY Performance
ANVS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$5.5M | $-0.32 |
| Q3 2025 | N/A | -$1.1M | $-0.37 |
| Q2 2025 | N/A | -$1.1M | $-0.32 |
| Q1 2025 | N/A | -$1.1M | $-0.32 |
| Q3 2024 | N/A | -$1.1M | $-0.97 |
| Q2 2024 | N/A | -$1.1M | $-0.44 |
| Q1 2024 | N/A | -$1.1M | $-0.72 |
| Q3 2023 | N/A | -$5.2M | $-0.79 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Annovis Bio, Inc. Dividends, Buybacks & Capital Allocation
ANVS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Annovis Bio, Inc. (CIK: 0001477845)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANVS
What is the AI rating for ANVS?
Annovis Bio, Inc. (ANVS) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANVS's key strengths?
Claude: No long-term debt eliminates near-term solvency risk from external creditors. Maintains positive cash reserves of $14.2M providing limited runway for operations and clinical development. ChatGPT: Strong cash balance relative to liabilities supports near-term operations. Debt-free capital structure reduces financial distress risk.
What are the risks of investing in ANVS?
Claude: Zero revenue generation with no evidence of commercially viable products. Negative operating cash flow of -$9M annually with limited cash runway (~1.5 years at current burn rate). ChatGPT: No revenue base means fundamentals depend entirely on future pipeline execution. High cash burn and negative operating cash flow could force future capital raises.
What is ANVS's revenue and growth?
Annovis Bio, Inc. reported revenue of $0.0.
Does ANVS pay dividends?
Annovis Bio, Inc. does not currently pay dividends.
Where can I find ANVS SEC filings?
Official SEC filings for Annovis Bio, Inc. (CIK: 0001477845) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANVS's EPS?
Annovis Bio, Inc. has a diluted EPS of $-0.63.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ANVS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Annovis Bio, Inc. has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ANVS stock overvalued or undervalued?
Valuation metrics for ANVS: ROE of -563.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ANVS's AI grade for 2026?
Our dual AI analysis gives Annovis Bio, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANVS's free cash flow?
Annovis Bio, Inc.'s operating cash flow is $-9.0M, with capital expenditures of N/A.
How does ANVS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -563.2% (avg: 15%), current ratio 0.61 (avg: 2).